FDA Partial Hold Halts U.S. Phase 2 Pediatric Epilepsy Trial; Shares Plunge 55%
DRUG is trading near its 52-week low of $18.9 (7.6% above the low) on elevated volume (4.1× avg).
Summary
The FDA placed a partial clinical hold on Bright Minds' IND and protocol for developmental and epileptic encephalopathies, blocking the planned U.S. Phase 2 trial of BMB-101 while other studies continue. Regulators cited toxicity seen in mice plus inadequate pharmacokinetic and juvenile toxicity data to support pediatric enrollment. The company argues the mouse finding was incidental rather than drug-related, but concedes those are its own interpretations, not FDA conclusions. Shares fell 55% to $24.72 on the news. The formal Partial Clinical Hold Letter is due within 30 days and will spell out the trial-design fixes required; management warned future U.S. trials may need additional data or studies and gave no assurance the hold gets lifted.
Updates
· SEC 6-K — Bright Minds said the FDA's partial clinical hold email cited mouse toxicity and inadequate pharmacokinetic and juvenile toxicity data, and that the full hold letter is due within 30 days.
At the time of this announcement, DRUG was trading at $20.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $542.3M. The 52-week trading range was $18.90 to $123.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Benzinga.